Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 653

1.

Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.

Han Q, Bradley T, Williams WB, Cain DW, Montefiori DC, Saunders KO, Parks RJ, Edwards RW, Ferrari G, Mueller O, Shen X, Wiehe KJ, Reed S, Fox CB, Rountree W, Vandergrift NA, Wang Y, Sutherland LL, Santra S, Moody MA, Permar SR, Tomaras GD, Lewis MG, Van Rompay KKA, Haynes BF.

Cell Rep. 2020 Feb 4;30(5):1553-1569.e6. doi: 10.1016/j.celrep.2019.12.091.

2.

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Easterhoff D, Pollara J, Luo K, Janus B, Gohain N, Williams LD, Tay MZ, Monroe A, Peachman K, Choe M, Min S, Lusso P, Zhang P, Go EP, Desaire H, Bonsignori M, Hwang KK, Beck C, Kakalis M, O'Connell RJ, Vasan S, Kim JH, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Arthos J, Rao M, Joyce MG, Ofek G, Ferrari G, Haynes BF.

JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437.

3.

Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements.

Henderson R, Lu M, Zhou Y, Mu Z, Parks R, Han Q, Hsu AL, Carter E, Blanchard SC, Edwards RJ, Wiehe K, Saunders KO, Borgnia MJ, Bartesaghi A, Mothes W, Haynes BF, Acharya P, Munir Alam S.

Nat Commun. 2020 Jan 24;11(1):520. doi: 10.1038/s41467-019-14196-w.

4.

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth.

Roskin KM, Jackson KJL, Lee JY, Hoh RA, Joshi SA, Hwang KK, Bonsignori M, Pedroza-Pacheco I, Liao HX, Moody MA, Fire AZ, Borrow P, Haynes BF, Boyd SD.

Nat Immunol. 2020 Feb;21(2):199-209. doi: 10.1038/s41590-019-0581-0. Epub 2020 Jan 20.

PMID:
31959979
5.

Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans.

Wu NR, Nicely NI, Lee EM, Reed RK, Watts BE, Cai F, Walkowicz WE, Aussedat B, Jones JA, Eaton A, Trama AM, Alam SM, Montefiori DC, Haynes BF, Saunders KO.

PLoS Pathog. 2019 Dec 16;15(12):e1008165. doi: 10.1371/journal.ppat.1008165. eCollection 2019 Dec.

6.

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF.

Science. 2019 Dec 6;366(6470). pii: eaay7199. doi: 10.1126/science.aay7199. No abstract available.

PMID:
31806786
7.

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 Dec 2;15(12):e1008200. doi: 10.1371/journal.ppat.1008200. eCollection 2019 Dec.

8.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.

Easterhoff D, Pollara J, Luo K, Tolbert WD, Young B, Mielke D, Jha S, O'Connell RJ, Vasan S, Kim J, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Pazgier M, Haynes BF, Ferrari G.

J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19. Print 2020 Jan 31.

9.

Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology.

D'Souza MP, Rele S, Haynes BF, Hu DJ, Kaplan DL, Mamaghani S, Rampulla D.

Vaccine. 2020 Jan 10;38(2):187-193. doi: 10.1016/j.vaccine.2019.10.036. Epub 2019 Nov 20.

PMID:
31759734
10.

Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection.

Paes W, Leonov G, Partridge T, Chikata T, Murakoshi H, Frangou A, Brackenridge S, Nicastri A, Smith AG, Learn GH, Li Y, Parker R, Oka S, Pellegrino P, Williams I, Haynes BF, McMichael AJ, Shaw GM, Hahn BH, Takiguchi M, Ternette N, Borrow P.

Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24748-24759. doi: 10.1073/pnas.1911622116. Epub 2019 Nov 20.

11.

Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5.

Finney J, Yang G, Kuraoka M, Song S, Nojima T, Verkoczy L, Kitamura D, Haynes BF, Kelsoe G.

J Immunol. 2019 Dec 15;203(12):3268-3281. doi: 10.4049/jimmunol.1900069. Epub 2019 Nov 15.

PMID:
31732530
12.

Multiple roles for HIV broadly neutralizing antibodies.

Haynes BF, Burton DR, Mascola JR.

Sci Transl Med. 2019 Oct 30;11(516). pii: eaaz2686. doi: 10.1126/scitranslmed.aaz2686. Review.

PMID:
31666399
13.

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 Sep 17;15(9):e1008026. doi: 10.1371/journal.ppat.1008026. eCollection 2019 Sep. Erratum in: PLoS Pathog. 2019 Dec 2;15(12):e1008200.

14.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

15.

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Wee EG, Moyo NA, Saunders KO, LaBranche C, Donati F, Capucci S, Parks R, Borthwick N, Hannoun Z, Montefiori DC, Haynes BF, Hanke T.

Mol Ther Methods Clin Dev. 2019 Jun 29;14:148-160. doi: 10.1016/j.omtm.2019.06.003. eCollection 2019 Sep 13.

16.

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Nyanhete TE, Frisbee AL, Bradley T, Faison WJ, Robins E, Payne T, Freel SA, Sawant S, Weinhold KJ, Wiehe K, Haynes BF, Ferrari G, Li QJ, Moody MA, Tomaras GD.

Sci Rep. 2019 Jul 15;9(1):10165. doi: 10.1038/s41598-019-46462-8.

17.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO.

Nat Commun. 2019 Jul 1;10(1):2898. doi: 10.1038/s41467-019-10899-2.

18.

Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.

Francica JR, Laga R, Lynn GM, Mužíková G, Androvič L, Aussedat B, Walkowicz WE, Padhan K, Ramirez-Valdez RA, Parks R, Schmidt SD, Flynn BJ, Tsybovsky Y, Stewart-Jones GBE, Saunders KO, Baharom F, Petrovas C, Haynes BF, Seder RA.

PLoS Biol. 2019 Jun 17;17(6):e3000328. doi: 10.1371/journal.pbio.3000328. eCollection 2019 Jun.

19.

The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template.

Andrabi R, Pallesen J, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR.

Cell Rep. 2019 May 21;27(8):2426-2441.e6. doi: 10.1016/j.celrep.2019.04.082.

20.

Self-tolerance curtails the B cell repertoire to microbial epitopes.

Watanabe A, Su KY, Kuraoka M, Yang G, Reynolds AE, Schmidt AG, Harrison SC, Haynes BF, St Clair EW, Kelsoe G.

JCI Insight. 2019 May 16;4(10). pii: 122551. doi: 10.1172/jci.insight.122551. eCollection 2019 May 16.

21.

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.

Cheng C, Xu K, Kong R, Chuang GY, Corrigan AR, Geng H, Hill KR, Jafari AJ, O'Dell S, Ou L, Rawi R, Rowshan AP, Sarfo EK, Sastry M, Saunders KO, Schmidt SD, Wang S, Wu W, Zhang B, Doria-Rose NA, Haynes BF, Scorpio DG, Shapiro L, Mascola JR, Kwong PD.

PLoS One. 2019 Apr 17;14(4):e0215163. doi: 10.1371/journal.pone.0215163. eCollection 2019.

22.

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques.

Pardi N, LaBranche CC, Ferrari G, Cain DW, Tombácz I, Parks RJ, Muramatsu H, Mui BL, Tam YK, Karikó K, Polacino P, Barbosa CJ, Madden TD, Hope MJ, Haynes BF, Montefiori DC, Hu SL, Weissman D.

Mol Ther Nucleic Acids. 2019 Apr 15;15:36-47. doi: 10.1016/j.omtn.2019.03.003. Epub 2019 Mar 21.

23.

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2019 Mar 26;15(3):e1007646. doi: 10.1371/journal.ppat.1007646. eCollection 2019 Mar.

24.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
25.

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, Weissenhorn W, Hogan MJ, Jordan APO, Gelman RS, Montefiori DC, Liao HX, Schmitz JE, Haynes BF, von Laer D, Kimpel J.

Viruses. 2019 Feb 15;11(2). pii: E159. doi: 10.3390/v11020159.

26.

Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies.

Henderson R, Watts BE, Ergin HN, Anasti K, Parks R, Xia SM, Trama A, Liao HX, Saunders KO, Bonsignori M, Wiehe K, Haynes BF, Alam SM.

Nat Commun. 2019 Feb 8;10(1):654. doi: 10.1038/s41467-019-08415-7.

27.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

28.

Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, Bonsignori M, Kanekiyo M, Wheatley AK, McDermott AB, Farney SK, Chuang GY, Zhang B, Kc N, Chakravarty S, Kwong PD, Sinnis P, Bhatia SN, Kappe SHI, Sim BKL, Hoffman SL, Zavala F, Pancera M, Seder RA.

Nat Med. 2019 Jan;25(1):188-189. doi: 10.1038/s41591-018-0315-0.

PMID:
30552419
29.

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.

Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF.

Immunity. 2018 Dec 18;49(6):1162-1174.e8. doi: 10.1016/j.immuni.2018.10.015. Epub 2018 Dec 11.

30.

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity.

van Eeden C, Wibmer CK, Scheepers C, Richardson SI, Nonyane M, Lambson B, Mkhize NN, Vijayakumar B, Sheng Z, Stanfield-Oakley S, Bhiman JN, Bekker V, Hermanus T, Mabvakure B, Ismail A, Moody MA, Wiehe K, Garrett N, Karim SA, Dirr H, Fernandes MA, Sayed Y, Shapiro L, Ferrari G, Haynes BF, Moore PL, Morris L.

Cell Rep. 2018 Dec 11;25(11):3123-3135.e6. doi: 10.1016/j.celrep.2018.11.058.

31.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov. Erratum in: PLoS Pathog. 2019 Mar 26;15(3):e1007646.

32.

Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth.

Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, Hraber PT, Decker TG, Smith AG, Gondim MV, Gillis L, Wandzilak J, Chuang GY, Rawi R, Cai F, Pellegrino P, Williams I, Overbaugh J, Gao F, Kwong PD, Haynes BF, Shaw GM, Borrow P, Seaman MS, Hahn BH, Korber B.

Cell Rep. 2018 Oct 23;25(4):893-908.e7. doi: 10.1016/j.celrep.2018.09.087.

33.

Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency.

Bradley T, Ferrari G, Haynes BF, Margolis DM, Browne EP.

Cell Rep. 2018 Oct 2;25(1):107-117.e3. doi: 10.1016/j.celrep.2018.09.020.

34.

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.

Blasi M, Negri D, LaBranche C, Alam SM, Baker EJ, Brunner EC, Gladden MA, Michelini Z, Vandergrift NA, Wiehe KJ, Parks R, Shen X, Bonsignori M, Tomaras GD, Ferrari G, Montefiori DC, Santra S, Haynes BF, Moody MA, Cara A, Klotman ME.

Commun Biol. 2018 Sep 5;1:134. doi: 10.1038/s42003-018-0131-6. eCollection 2018.

35.

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses.

Bradley T, Peppa D, Pedroza-Pacheco I, Li D, Cain DW, Henao R, Venkat V, Hora B, Chen Y, Vandergrift NA, Overman RG, Edwards RW, Woods CW, Tomaras GD, Ferrari G, Ginsburg GS, Connors M, Cohen MS, Moody MA, Borrow P, Haynes BF.

Cell. 2018 Oct 4;175(2):387-399.e17. doi: 10.1016/j.cell.2018.08.064. Epub 2018 Sep 27.

36.

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.

Ackerman ME, Das J, Pittala S, Broge T, Linde C, Suscovich TJ, Brown EP, Bradley T, Natarajan H, Lin S, Sassic JK, O'Keefe S, Mehta N, Goodman D, Sips M, Weiner JA, Tomaras GD, Haynes BF, Lauffenburger DA, Bailey-Kellogg C, Roederer M, Alter G.

Nat Med. 2018 Oct;24(10):1590-1598. doi: 10.1038/s41591-018-0161-0. Epub 2018 Sep 3.

37.

Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection.

Vaidya NK, Ribeiro RM, Liu P, Haynes BF, Tomaras GD, Perelson AS.

Front Microbiol. 2018 Jun 20;9:1326. doi: 10.3389/fmicb.2018.01326. eCollection 2018.

38.

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge.

Madani N, Princiotto AM, Mach L, Ding S, Prevost J, Richard J, Hora B, Sutherland L, Zhao CA, Conn BP, Bradley T, Moody MA, Melillo B, Finzi A, Haynes BF, Smith Iii AB, Santra S, Sodroski J.

Nat Commun. 2018 Jun 18;9(1):2363. doi: 10.1038/s41467-018-04758-9.

39.

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.

Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, Faison WJ, Kepler TB, Saunders KO, Alam SM, Bonsignori M, Haynes BF.

Cell Host Microbe. 2018 Jun 13;23(6):759-765.e6. doi: 10.1016/j.chom.2018.04.018. Epub 2018 May 31.

40.

Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection.

Song H, Giorgi EE, Ganusov VV, Cai F, Athreya G, Yoon H, Carja O, Hora B, Hraber P, Romero-Severson E, Jiang C, Li X, Wang S, Li H, Salazar-Gonzalez JF, Salazar MG, Goonetilleke N, Keele BF, Montefiori DC, Cohen MS, Shaw GM, Hahn BH, McMichael AJ, Haynes BF, Korber B, Bhattacharya T, Gao F.

Nat Commun. 2018 May 15;9(1):1928. doi: 10.1038/s41467-018-04217-5.

41.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

42.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

43.

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, Bonsignori M, Kanekiyo M, Wheatley AK, McDermott AB, Farney SK, Chuang GY, Zhang B, Kc N, Chakravarty S, Kwong PD, Sinnis P, Bhatia SN, Kappe SHI, Sim BKL, Hoffman SL, Zavala F, Pancera M, Seder RA.

Nat Med. 2018 May;24(4):408-416. doi: 10.1038/nm.4512. Epub 2018 Mar 19. Erratum in: Nat Med. 2019 Jan;25(1):188-189.

44.

HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.

Fera D, Lee MS, Wiehe K, Meyerhoff RR, Piai A, Bonsignori M, Aussedat B, Walkowicz WE, Ton T, Zhou JO, Danishefsky S, Haynes BF, Harrison SC.

Nat Commun. 2018 Mar 16;9(1):1111. doi: 10.1038/s41467-018-03565-6.

45.

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.

Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Karlsson Hedestam GB, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME.

JCI Insight. 2018 Mar 8;3(5). pii: 97018. doi: 10.1172/jci.insight.97018.

46.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.

Saunders KO, Santra S, Parks R, Yates NL, Sutherland LL, Scearce RM, Balachandran H, Bradley T, Goodman D, Eaton A, Stanfield-Oakley SA, Tartaglia J, Phogat S, Pantaleo G, Esteban M, Gomez CE, Perdiguero B, Jacobs B, Kibler K, Korber B, Montefiori DC, Ferrari G, Vandergrift N, Liao HX, Tomaras GD, Haynes BF.

J Virol. 2018 Mar 28;92(8). pii: e02035-17. doi: 10.1128/JVI.02035-17. Print 2018 Apr 15.

47.

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD.

J Virol. 2018 Mar 28;92(8). pii: e01843-17. doi: 10.1128/JVI.01843-17. Print 2018 Apr 15.

48.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

49.

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.

Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD.

J Virol. 2018 Mar 14;92(7). pii: e01552-17. doi: 10.1128/JVI.01552-17. Print 2018 Apr 1.

50.

Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, Housman M, Bouton-Verville H, Shen X, Trama AM, Scearce R, Sutherland L, Santra S, Newman A, Eaton A, Xu K, Georgiev IS, Joyce MG, Tomaras GD, Bonsignori M, Reed SG, Salazar A, Mascola JR, Moody MA, Cain DW, Centlivre M, Zurawski S, Zurawski G, Erickson HP, Kwong PD, Alam SM, Levy Y, Montefiori DC, Haynes BF.

Cell Rep. 2017 Dec 26;21(13):3681-3690. doi: 10.1016/j.celrep.2017.12.028.

Supplemental Content

Loading ...
Support Center